Containing global antibiotic resistance: Ethical drug promotion in the developing world

Antimicrobial Resistance in Developing Countries

Volumn 9780387893709, Issue , 2010, Pages 505-524

  Olivier, Catherine ^a   Williams Jones, Bryn ^a   Doizé, Béatrice ^a   Ozdemir, Vural ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84874120406     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-89370-9_29     Document Type: Chapter

References (89)

1. Aarestrup, F. M. 2005. Veterinary drug usage and antimicrobial resistance in bacteria of animal origin. Basic Clin Pharmacol Toxicol 96:271-281.
2. Anthony, F., Acar, J., Franklin, A., Gupta, R., Nicholls, T., Tamura, Y., et al. 2001. Antimicrobial resistance: responsible and prudent use of antimicrobial agents in veterinary medicine. Rev Sci Tech 20:829-839.
3. Bancroft, E. A. 2007. Antimicrobial resistance: it's not just for hospitals. JAMA 298:1803-1804.
4. Barza, M. and Gorbach, S. 2002. The need to improve microbial use in agriculture: ecology and human health consequences. Clin Infect Dis 34:S71-S144.
5. BBC News. 2005. Brazil may break Aids drug patent. Brazil has threatened to break the patent on an anti-Aids drug in order to make a cheaper generic version. http://news.bbc. co.uk/go/pr/fr/-/2/hi/americas/4621735.stm.
6. BBC News. 2007. Uganda opens first HIV drug plant. A factory that will produce treatments for HIV/Aids is opening in Uganda, the first of its kind in the country http://news.bbc.co. uk/2/hi/africa/7033162.stm.
7. Benkimoun, P. 2005. Le paludisme, un tueur du tiers-monde. Le Monde. Paris.
8. Bhutta, T. I. 1996. Deception by design: pharmaceutical promotion in the Third World. Br Med J 313:60.
9. Brodie, M. and Levitt, L. 2002. Drug advertising: the right or wrong prescription for our ailments? Nat Rev Drug Discov 1:916-920.
10. Byarugaba, D. K. 2004. A view on antimicrobial resistance in developing countries and responsible risk factors. Int J Antimicrob Agents 24:105-110.
11. Corpet, D. E. 1988. Antibiotic resistance from food. N Engl J Med 318:1206-1207.
12. Dal-Pizzol, F. 2002. Drug advertisements in less-developed countries. Lancet 359:1439-1440.
13. Deshpande, A., Menon, A., Perri, M., 3rd and Zinkhan, G. 2004. Direct-to-consumer advertising and its utility in health care decision making: a consumer perspective. J Health Commun 9:499-513.
14. Dipeolu, M. and Alonge, D. 2002. Residues of streptomycin antibiotic in meat sold for human consumption in some states in Nigeria. Arch Zootec 51:477-480.
15. Donald, A. 1999. Technology transfer: the problem with "trickle down" theory. Br Med J 319:1298-1299.
16. Dugger, C. W. 2007. U. N. predicts urban population explosion. The New York Times. New York.
17. Dukes, G. M. N. 2002. Accountability of the pharmaceutical industry. Lancet 360:1682-1684.
18. Fidler, D. P. 1998. Legal issues associated with antimicrobial drug resistance. Emerg Infect Dis 4:169-177.
19. Findlay, S. D. 2001. Direct-to-consumer promotion of prescription drugs. Economic implications for patients, payers and providers. Pharmacoeconomics 19:109-119.
20. Garcia-Rey, C., Aguilar, L., Baquero, F., Casal, J. and Martin, J. E. 2002. Pharmacoepidemiological analysis of provincial differences between consumption of macrolides and rates of erythromycin resistance among Streptococcus pyogenes isolates in Spain. J Clin Microbiol 40:2959-2963.
21. Gassman, N. 1999. Social and economic value: two sides of the self-medication coin. Responsible self-medication: a challenge to consumers and industry. The World Self-Medication Industry (WSMI) 13th General Assembly, The Association of the European Self-Medication Industry (AESGP) 35th Annual Meeting, Self-care - a vital element of health policy in the information age. Berlin.
22. Gaur, A. H. and English, B. K. 2006. The judicious use of antibiotics - an investment towards optimized health care. Indian J Pediatr 73:343-350.
23. Harris, G. 2007. Minnesota limit on gifts to doctors may catch on. The New York Times. New York.
24. Hart, C. A. and Kariuki, S. 1998. Antimicrobial resistance in developing countries. Br Med J 317:647-650.
25. Heath, J. 2006. Business ethics without stakeholders. Bus Ethics Q 16:533-557.
26. Hodges, B. 1995. Interactions with the pharmaceutical industry: experiences and attitudes of psychiatry residents, interns and clerks. CMAJ 153:553-559.
27. Hoek, J. and Gendall, P. 2002. Direct-to-consumer advertising down under: an alternative perspective and regulatory framework. J Public Policy Mark 21:202-212.
28. Hogerzeil, H. V. 2004. The concept of essential medicines: lessons for rich countries. 329:1169-1172.
29. Islam, M. S. and Farah, S. S. 2007. Misleading promotion of drugs in Bangladesh: evidence from drug promotional brochures distributed to general practitioners by the pharmaceutical companies. J Public Health (Oxf) 29:212-213.
30. Jaderberg, M. 2002. The pharmaceutical industry - a key partner in providing information to the patient anda key player inthe European debate ondirect to consumer communication. Int J Med Mark 2:179-183.
31. Katz, D., Caplan, A. L. and Merz, J. F. 2003. All gifts large and small. Am J Bioeth 3:39-46.
32. Klevens, R. M., Morrison, M. A., Nadle, J., Petit, S., Gershman, K., Ray, S., et al. 2007. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298:1763-1771.
33. Kolawole, D. and Shittu, A. 1997. Unusual recovery of animal staphylococci from septic wounds of hospital patients in Ile-Ife, Nigeria. Lett Appl Microbiol 24:87-90.
34. Kumarasamy, N., Safren, S. A., Raminani, S. R., Pickard, R., James, R., Krishnan, A. K., et al. 2005. Barriers and facilitators to antiretroviral medication adherence among patients with HIV in Chennai, India: a qualitative study. AIDS Patient Care STDS 19:526-537.
35. Kunin, C. M. 1993. Resistance to antimicrobial drugs - a worldwide calamity. Ann Intern Med 118:557-561.
36. Lal, A. 1998. Information contents of drug advertisements: an Indian experience. Ann Pharmacother 32:1234-1238.
37. Lexchin, J. 1987. Advertisement scrutiny. Lancet 1:1323-1324.
38. Lu, H. Z., Weng, X. H., Li, H., Yin, Y. K., Pang, M. Y. and Tang, Y. W. 2002. Enterococcus faecium-related outbreak with molecular evidence of transmission from pigs to humans. J Clin Microbiol 40:913-917.
39. Master, Z. and Ozdemir, V. 2008. Selling translational research: is science a value-neutral autonomous enterprise? Am J Bioeth 8(3):52-54
40. Mastin, T., Andsager, J. L., Choi, J. and Lee, K. 2007. Health disparities and direct-to-consumer prescription drug advertising: a content analysis of targeted magazine genres, 1992-2002. Health Commun 22:49-58.
41. McCaig, L. F., Besser, R. E. and Hughes, J. M. 2002. Trends in antimicrobial prescribing rates for children and adolescents. JAMA 287:3096-3102.
42. McCaig, L. F., Besser, R. E. and Hughes, J. M. 2003. Antimicrobial drug prescription in ambulatory care settings, United States, 1992-2000. Emerg Infect Dis 9:432-437.
43. McCaig, L. F., Hooker, R. S., Sekscenski, E. S. and Woodwell, D. A. 1998. Physician assistants and nurse practitioners in hospital outpatient departments, 1993-1994. Public Health Rep 113:75-82.
44. Menkes, D. B. 1997. Hazardous drugs in developing countries. Br Med J 315:1557-1558.
45. Menkes, D. B. 2006. Calling the piper's tune. Primary Care Commun Psychiatry 11:147-149.
46. Mintzes, B. 1998. Blurring the boundaries: new trends in drug promotion. In: Promotion Targeting Consumers. Amsterdam: HAI-Europe www.haiweb.org/pubs/blurring/blurring. intro.html Dated Accessed January 20, 2009.
47. Mintzes, B. 2006. Disease mongering in drug promotion: do governments have a regulatory role? PLoS Med 3:e198.
48. Mitema, E. S., Kikuvi, G. M., Wegener, H. C. and Stohr, K. 2001. An assessment of antimicrobial consumption in food producing animals in Kenya. J Vet Pharmacol Ther 24:385-390.
49. MSNBC. 2006. WHO calls for halt onmalaria treatment. Agency fears improper use may lead to drug resistance. Associated Press.
50. Muriuki, F. K., Ogara, W. O., Njeruh, F. M. and Mitema, E. S. 2001. Tetracycline residue levels in cattle meat from Nairobi slaughter house in Kenya. J Vet Sci 2:97-101.
51. Mutume, G. 2001. Health and intellectual property; poor nations and drug firms tussle over WTO patent provisions. Africa Recover 15(1):14-15.
52. Na Iampang, K., Chongsuvivatwong, V. and Kitikoon, V. 2007. Pattern and determinant of antibiotics used on broiler farms in Songkhla province, southern Thailand. Trop Anim Health Prod 39:355-361.
53. Nicholls, T., Acar, J., Anthony, F., Franklin, A., Gupta, R., Tamura, Y., et al. 2001. Antimicrobial resistance: monitoring the quantities of antimicrobials used in animal husbandry. Rev Sci Tech. 20:841-847.
54. Norris, P., Herxheimer, A., Lexchin, J. and Mansfield, P. 2005. Drug promotion. What we know, what we have yet to learn. Reviews of materials in the WHO/HAI database on drug promotion. Amsterdam: WHO/HAI.
55. Okeke, I. N., Klugman, K. P., Bhutta, Z. A., Duse, A. G., Jenkins, P., O'Brien, T. F., et al. 2005. Antimicrobial resistance in developing countries. Part II: strategies for containment. Lancet Infect Dis 5:568-580.
56. Okeke, I. N., Lamikanra, A. and Edelman, R. 1999. Socioeconomic and behavioral factors leading to acquired bacterial resistance to antibiotics in developing countries. Emerg Infect Dis 5:18-27.
57. Oyugi, J. H., Byakika-Tusiime, J., Charlebois, E. D., Kityo, C., Mugerwa, R., Mugyenyi, P., et al. 2004. Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. J Acquir Immune Defic Syndr 36:1100-1102.
58. Ozdemir, V., Aklillu, E., Mee, S., Bertilsson, L., Albers, L., Graham, J. E., et al. 2006. Pharmacogenetics for off-patent antipsychotics: reframing the risk for tardive dyskinesia and access to essential medicines. Expert Opin Pharmacother 7:119-133.
59. Ozdemir, V. and Godard, B. 2007. Evidence-based management of nutrigenomics expectations and ELSIs. Pharmacogenomics 8:1051-1062.
60. Ozdemir, V., Graham, J. E. and Godard, B. 2008. Race as a variable in pharmacogenomics research: From empirical ethics to publication standards. Pharmacogenet Genomics 18(10):837-841.
61. Petersen, A., Andersen, J., Kaewmak, T., Somsiri, T. and Dalsgaard, A. 2002. Impact of integrated fish farming on antimicrobial resistance in a pond environment. Appl Environ Microbiol 68:6036-6042.
62. Phillips, I., Casewell, M., Cox, T., De Groot, B., Friis, C., Jones, R., et al. 2004. Does the use of antibiotics in food animals pose a risk to human health? A critical review of published data. J Antimicrob Chemother 53:28-52.
63. Projan, S. J. 2003. Why is big Pharma getting out of antibacterial drug discovery? Curr Opin Microbiol 6:427-430.
64. Quick, J. D. 2003. Ensuring access to essential medicines in the developing countries: a framework for action. Clin Pharmacol Ther. 73:279-283.
65. Richet, H. M., Mohammed, J., McDonald, L. C. and Jarvis, W. R. 2001. Building communication networks: international network for the study and prevention of emerging antimicrobial resistance. Emerg Infect Dis 7:319-322.
66. Rogers, W. A., Mansfield, P. R., Braunack-Mayer, A. J. and Jureidini, J. N. 2004. The ethics of pharmaceutical industry relationships with medical students. Med J Aust 180:411-414.
67. Rolland, R. M., Hausfater, G., Marshall, B. and Levy, S. B. 1985. Antibiotic-resistant bacteria in wild primates: increased prevalence in baboons feeding on human refuse. Appl Environ Microbiol 49:791-794.
68. Rollin, B. 2001. Ethics, science and antimicrobial resistance. J. Agric Environ Ethics 14:29-37.
69. Semin, S., Aras, S. and Guldal, D. 2007. Direct-to-consumer advertising of pharmaceuticals: developed countries experiences and Turkey. Health Expect 10:4-15.
70. Simango, C. and Rukure, G. 1991. Potential sources of campylobacter species in the homes of farmworkers in Zimbabwe. J Trop Med Hyg 94:388-392.
71. Spear, B. B., Heath-Chiozzi, M. and Huff, J. 2001. Clinical application of pharmacogenetics. Trends Mol Med 7:201-204.
72. Spellberg, B., Powers, J. H., Brass, E. P., Miller, L. G. and Edwards, J. E., Jr. 2004. Trends in antimicrobial drug development: implications for the future. Clin Infect Dis 38:1279-1286.
73. Talbot, G. H., Bradley, J., Edwards, J. E., Jr., Gilbert, D., Scheld, M. and Bartlett, J. G. 2006. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 42:657-668.
74. Tuffs, A. 2004. Only 6% of drug advertising material is supported by evidence. Br Med J 328:485.
75. Usluer, G., Ozgunes, I. and Leblebicioglu, H. 2005. A multicenter point-prevalence study: antimicrobial prescription frequencies in hospitalized patients in Turkey. Ann Clin Microbiol Antimicrob 4:16.
76. Vancelik, S., Beyhun, N. E., Acemoglu, H. and Calikoglu, O. 2007. Impact of pharmaceutical promotion on prescribing decisions of general practitioners in Eastern Turkey. BMC Public Health 7:122.
77. Vidaver, A. K. 2002. Uses of antimicrobials in plant agriculture. Clin Infect Dis 34 Suppl 3:S107-S110.
78. Waud, D. 1992. Pharmaceutical promotions - a free lunch? N Engl J Med. 327:351-353.
79. Wazana, A. 2000. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA 283:373-380.
80. World Consumer Rights Day (WCRD). 2007. Unethical Drug Promotion.
81. Wenzel, R. P. 2004. The antibiotic pipeline - challenges, costs, and values. N Engl J Med 351:523-526.
82. World Health Organization. (WHO) http://www.who.int/medicines/en.
83. World Health Organization. (WHO). 1988. Criteria for medicinal drug promotion. Geneva: World Health Organization.
84. World Health Organization. (WHO). 1998. Emerging and other communicable diseases: antimicrobial resistance. Geneva: World Health Organization.
85. World Health Organization. (WHO). 2001. Pharmaceutical promotion. IN WHO global strategy for containment of antimicrobial resistance. Executive Summary, World Health Organization (Ed.). 51-53. Geneva: World Health Organization.
86. WHO. 2006. Facts on acts (artemisinin-based combination therapies). Geneva: World Health Organization.
87. WHO. 2007. Resistance to artemisinin derivatives along the Thai-Cambodian border. Weekly Epidemiol Rec 82(41):360.
88. Yamey, G. 2001. US trade action threatens Brazilian AIDS programme. Br Med J 322:383.
89. Yoshikawa, T. T. 2002. Antimicrobial resistance and aging: beginning of the end of the antibiotic era? J Am Geriatr Soc 50:S226-S229.